Hellmann MD, Rizi NA, Goldman GW, et al. Nivolumab plus ipilimumab as first- line treatment for advanced non -small -cell lung cancer (CheckMate 012): results of an open - label, phase 1, multicohort study .Lancet Oncol. 2017 Jan;18(1):31-41.